Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Talphera

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 15

Market Cap: $16.4M

Website

Introduction: Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

Clinical Trials

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

Not Applicable

Recruiting

Conditions: Acute Kidney Injury

Interventions: Device: Niyad (nafamostat mesylate)
Device: Placebo (0.9% NaCl)

First Posted Date: 2023-11-29

Last Posted Date: 2024-10-14

Lead Sponsor: Talphera, Inc

Target Recruit Count: 166

Registration Number: NCT06150742

Locations: 🇺🇸
Wake Forest, Winston-Salem, North Carolina, United States

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

Phase 3

Completed

Conditions: Moderate-to-severe Acute Pain

Interventions: Drug: Zalviso™ 15 mcg

First Posted Date: 2016-01-26

Last Posted Date: 2018-08-08

Lead Sponsor: Talphera, Inc

Target Recruit Count: 320

Registration Number: NCT02662764

Locations: 🇺🇸
Eliza Coffee Memorial Hospital, Florence, Alabama, United States
🇺🇸
Shoals Medical Trials, Sheffield, Alabama, United States
🇺🇸
Arizona Research Center, Phoenix, Arizona, United States

and more 8 locations

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Phase 3

Completed

Conditions: Acute Moderate-to-severe Pain

Interventions: Drug: sufentanil sublingual tablet 30 mcg

First Posted Date: 2016-01-25

Last Posted Date: 2017-03-15

Lead Sponsor: Talphera, Inc

Target Recruit Count: 140

Registration Number: NCT02662556

Locations: 🇺🇸
HD Research, Houston, Texas, United States
🇺🇸
Research Concepts, Houston, Texas, United States

Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

Phase 3

Completed

Conditions: Moderate-to-severe Acute Pain

Interventions: Drug: sufentanil sublingual 30 mcg tablet

First Posted Date: 2015-05-19

Last Posted Date: 2017-10-19

Lead Sponsor: Talphera, Inc

Target Recruit Count: 76

Registration Number: NCT02447848

Locations: 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
🇺🇸
Hermann Memorial Medical Center, Houston, Texas, United States
🇺🇸
Ben Taub General Hospital, Houston, Texas, United States

A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

Phase 3

Completed

Conditions: Post-Operative Pain

Interventions: Drug: Placebo Tablet
Drug: Sufentanil Tablet 30 mcg

First Posted Date: 2015-02-05

Last Posted Date: 2017-02-13

Lead Sponsor: Talphera, Inc

Target Recruit Count: 161

Registration Number: NCT02356588

Locations: 🇺🇸
Shoals Medical Trials, Inc, Sheffield, Alabama, United States
🇺🇸
Lotus Clinical Research, Pasadena, California, United States
🇺🇸
Victory Medical Center, Houston, Texas, United States

and more 1 locations

Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2014-03-10

Last Posted Date: 2018-07-17

Lead Sponsor: Talphera, Inc

Target Recruit Count: 40

Registration Number: NCT02082236

Locations: 🇺🇸
PRA, Lenexa, Kansas, United States

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Phase 1

Completed

Conditions: Plasma Concentrations

Interventions: Drug: Single dose of SUF NT 15 mcg
Drug: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes

First Posted Date: 2013-01-07

Last Posted Date: 2015-10-01

Lead Sponsor: Talphera, Inc

Target Recruit Count: 40

Registration Number: NCT01761565

Locations: 🇺🇸
PRA, Lenexa, Kansas, United States

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Sufentanil NanoTab (SUF NT) 15 mcg
Drug: Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg

First Posted Date: 2012-11-04

Last Posted Date: 2016-11-04

Lead Sponsor: Talphera, Inc

Target Recruit Count: 19

Registration Number: NCT01721070

Locations: 🇺🇸
PRA, Lenexa, Kansas, United States

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Phase 2

Completed

Conditions: Acute Pain

Interventions: Drug: Sufentanil NanoTab 30 mcg
Drug: Placebo NanoTab
Drug: Sufentanil NanoTab 20 mcg

First Posted Date: 2012-10-19

Last Posted Date: 2015-01-26

Lead Sponsor: Talphera, Inc

Target Recruit Count: 101

Registration Number: NCT01710345

Locations: 🇺🇸
Lotus Clinical Research, Pasadena, California, United States
🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States

Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

Phase 3

Completed

Conditions: Post Operative Pain

Interventions: Drug: Placebo Sufentanil NanoTab PCA System
Drug: Sufentanil NanoTab PCA System/15 mcg

First Posted Date: 2012-08-09

Last Posted Date: 2015-10-20

Lead Sponsor: Talphera, Inc

Target Recruit Count: 419

Registration Number: NCT01660763

Locations: 🇺🇸
Deidre Stonestreet, Damascus, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy